Roivant Sciences CFO Richard Pulik Sells Shares
CFO Richard Pulik sold 2,129 shares of Roivant Sciences on June 20, 2026.
Key Points
- Roivant Sciences CFO Richard Pulik sold 2,129 shares valued at $66,914.47 on June 20, 2026, at an average price of $31.43.
- Shares of NasdaqGS:ROIV traded near $31.25 on Wednesday with a market cap of $22.48 billion and a forward P/E ratio of -20.04.
- FMR LLC increased its Roivant stake by 12.2 million shares, while Morgan Stanley reduced its holdings by 6.5 million shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Roivant Sciences Ltd.'s CFO, Richard Pulik, sold 2,129 shares of the company on June 20, 2026. The shares were sold at an average price of $31.43, amounting to a transaction value of $66,914.47. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Roivant Sciences Ltd.
Richard Pulik, the CFO of Roivant Sciences, sold 2,129 shares on June 20, 2026, at an average price of $31.43, totaling $66,914.47. The transaction was not conducted under a Rule 10b5-1 trading plan. On the same day, Chief Accounting Officer Jennifer Humes also sold 3,582 shares at the same price. Previously, on May 22, 2026, President and Immunovant CEO Eric Venker executed several transactions, including selling 200,000 shares at $30.27 as part of a planned sale.
Other Institutional Activity in Roivant Sciences
Several major institutional investors adjusted their positions in Roivant Sciences. FMR LLC increased its holdings by 12,201,789 shares, bringing its total to 77,981,253 shares valued at approximately $2.16 billion. Meanwhile, Morgan Stanley reduced its stake by 6,531,228 shares, ending with 51,828,325 shares worth about $1.44 billion. BlackRock, Inc. added 3,083,785 shares, reaching a total of 44,254,260 shares valued at $1.23 billion. UBS Group AG also increased its position significantly by 4,228,680 shares, totaling 22,619,472 shares worth $626.6 million. Vanguard Capital Management LLC opened a new position with 20,680,572 shares valued at $572.9 million.
Roivant Sciences Ltd. Stock Down 7.2%
Shares of Roivant Sciences Ltd. (NasdaqGS:ROIV) traded near $31.25 on Wednesday. The company has a market capitalization of $22.48 billion and a forward P/E ratio of -20.04, reflecting its unprofitability. Roivant's stock has seen a 52-week low of $10.71 and a high of $32.79. The company's 50-day moving average is $29.13, with a 200-day moving average of $23.56. Its current ratio stands at 18.37, with a quick ratio of 18.0 and a debt-to-equity ratio of 2.03.
$ROIV stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 26, 2026, Guggenheim maintained its 'buy' rating on Roivant Sciences with a price target of $36. Citigroup reiterated its 'buy' rating with a $42 target on May 21, 2026, while TD Cowen also maintained a 'buy' rating with a $41 target on the same day. The overall analyst consensus for Roivant is a 'strong buy', with a mean price target of $39.04 based on 12 analyst opinions.
About Roivant Sciences
Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom. Led by CEO Matthew Gline, the company focuses on discovering, developing, and commercializing innovative medicines and technologies. With 721 employees, Roivant is working on several clinical product candidates, including treatments for autoimmune and cardiopulmonary diseases. The company was founded in 2014 and operates within the biotechnology industry.
Bottom Line
The recent insider sale by Roivant Sciences' CFO, Richard Pulik, highlights ongoing activity within the company. Investors closely watch such transactions for insights into executive sentiment. With significant institutional movements and a strong 'buy' consensus from analysts, Roivant remains a key player in the biotechnology sector. However, it's important to remember that insider transactions like this one are disclosed after the fact and may not reflect current holdings.
Get Roivant Sciences Ltd. alerts
New 13F filings, insider trades, and analyst moves on $ROIV, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.